Please assess the completion status of the following clinical trial:

Trial Title: Alexa, What is Eliquis and Xarelto?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (Patients):~* 18 years of age or older~* Have been prescribed either apixaban or rivaroxaban during their inpatient stay~* Consent to participating in the study~Inclusion Criteria (Nurses):~* Providing direct patient care in select general medicine and orthopedic surgical units~* Consent to participating in the study~Exclusion Criteria:~* Patients will be excluded if they have documented altered mental status, do not speak English, or are being prescribed rivaroxaban or apixaban on discharge only.~* Nurses will be excluded if not providing direct patient care in select general medicine and orthopedic surgical units~* Nurses declining participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: NO_INTERVENTION): Patient's will receive standard education on Xarelto and Eliquis per usual process without use of Alexa based voice recording.
- Alexa Education (Type: ACTIVE_COMPARATOR): Patient's will opt in to receive initial education via Alexa based voice recording on Xarelto and Eliquis.

Based on this trial design, predict the completion outcome and termination type (if applicable).